DE69828682D1 - Nanomolare, non-peptidische inhibitoren von cathepsin d - Google Patents

Nanomolare, non-peptidische inhibitoren von cathepsin d

Info

Publication number
DE69828682D1
DE69828682D1 DE69828682T DE69828682T DE69828682D1 DE 69828682 D1 DE69828682 D1 DE 69828682D1 DE 69828682 T DE69828682 T DE 69828682T DE 69828682 T DE69828682 T DE 69828682T DE 69828682 D1 DE69828682 D1 DE 69828682D1
Authority
DE
Germany
Prior art keywords
cathepsin
nanomolar
peptidic inhibitors
peptidic
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69828682T
Other languages
English (en)
Other versions
DE69828682T2 (de
Inventor
K Kick
A Ellman
D Kuntz
E Lee
Guangcheng Liu
C Roe
Geoffrey Skillman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE69828682D1 publication Critical patent/DE69828682D1/de
Publication of DE69828682T2 publication Critical patent/DE69828682T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69828682T 1997-02-04 1998-02-03 Nanomolare, non-peptidische inhibitoren von cathepsin d Expired - Lifetime DE69828682T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3690397P 1997-02-04 1997-02-04
US36903P 1997-02-04
PCT/US1998/002199 WO1998033795A1 (en) 1997-02-04 1998-02-03 Nanomolar, non-peptide inhibitors of cathepsin d

Publications (2)

Publication Number Publication Date
DE69828682D1 true DE69828682D1 (de) 2005-02-24
DE69828682T2 DE69828682T2 (de) 2006-04-06

Family

ID=21891303

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69828682T Expired - Lifetime DE69828682T2 (de) 1997-02-04 1998-02-03 Nanomolare, non-peptidische inhibitoren von cathepsin d

Country Status (8)

Country Link
US (1) US6150416A (de)
EP (1) EP0958293B1 (de)
JP (1) JP2001510474A (de)
AT (1) ATE287402T1 (de)
AU (1) AU749281B2 (de)
CA (1) CA2280096A1 (de)
DE (1) DE69828682T2 (de)
WO (1) WO1998033795A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119105B2 (en) 1997-02-04 2006-10-10 The Regents Of The University Of California Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
US20020010550A1 (en) 1998-09-14 2002-01-24 George M. Grass Pharmacokinetic-based drug design tool and method
CA2367112A1 (en) * 1999-03-24 2000-09-28 The Regents Of The University Of California Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
JP2003519201A (ja) * 2000-01-03 2003-06-17 ザ トラスティーズ オブ プリンストン ユニバーシティ 機能特性に対する分子変種の高能率マッピング
EP1666452A2 (de) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Verbindungen zur Behandlung der Alzheimerischen Krankheit
EP1586556A3 (de) * 2000-06-30 2005-12-21 Elan Pharmaceuticals, Inc. Verbindungen zur Behandlung der Alzheimerischen Krankheit
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
DE60112942T2 (de) * 2000-06-30 2006-06-22 Elan Pharmaceuticals, Inc., South San Francisco Verbindungen zur behandlung der alzheimerischen krankheit
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20030211487A1 (en) * 2001-01-03 2003-11-13 Herschel Rabitz High efficiency mapping of molecular variations to functional properties
AR035960A1 (es) * 2001-04-23 2004-07-28 Elan Pharm Inc Epoxidos sustituidos y procesos para prepararlos
ATE396174T1 (de) * 2001-06-01 2008-06-15 Elan Pharm Inc Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
CA2462851A1 (en) 2001-10-04 2003-04-10 Elan Pharmaceuticals, Inc. Hydroxypropylamines
MXPA04004428A (es) 2001-11-08 2004-09-10 Elan Pharm Inc Derivados de 2,3-diamino-2-hidroxipropano n,n`-sustituidos.
US7338965B2 (en) 2001-11-19 2008-03-04 Pharmacia & Upjohn Company 3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines
AU2003303141A1 (en) 2002-04-30 2004-07-22 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer's disease
AU2003256305A1 (en) * 2002-06-24 2004-01-06 Axys Pharmaceuticals, Inc. Peptidic compounds as cysteine protease inhibitors
CN100384824C (zh) * 2002-09-10 2008-04-30 艾伦药物公司 乙酰基2-羟基-1,3-二氨基烷烃
UY27967A1 (es) * 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
GB0228410D0 (en) 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds
US7408008B2 (en) 2003-12-09 2008-08-05 Janssen Pharmaceutica, N.V. Method of producing highly functionalized 1,3-diamino-propan-2-ols from solid support
GB0328900D0 (en) * 2003-12-12 2004-01-14 Glaxo Group Ltd Novel compounds
AU2006228957A1 (en) * 2005-04-01 2006-10-05 Methylgene Inc. Inhibitors of histone deacetylase
ES2649964T3 (es) 2011-02-08 2018-01-16 Merck Patent Gmbh Derivados de aminoestatina para el tratamiento de la artrosis
JP6430936B2 (ja) 2012-07-24 2018-11-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 関節症の処置のためのヒドロキシスタチン誘導体
WO2014084430A1 (ko) * 2012-11-30 2014-06-05 경상대학교 산학협력단 병용 항암요법
CN105189469B (zh) 2013-02-25 2018-09-25 默克专利股份公司 2-氨基-3,4-二氢喹唑啉衍生物及其作为组织蛋白酶d抑制剂的用途
EP3030250B1 (de) 2013-08-06 2019-08-28 Merck Patent GmbH Intraartikuläre applikation von pepstatin bei arthrose

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604402A (en) * 1984-03-30 1986-08-05 E. R. Squibb & Sons, Inc. Hydroxy substituted ureido amino and imino acids
DK0735019T3 (da) * 1990-11-19 2000-10-23 Monsanto Co Retrovirale proteaseinhibitorer

Also Published As

Publication number Publication date
WO1998033795A1 (en) 1998-08-06
ATE287402T1 (de) 2005-02-15
CA2280096A1 (en) 1998-08-06
AU749281B2 (en) 2002-06-20
AU6268698A (en) 1998-08-25
JP2001510474A (ja) 2001-07-31
DE69828682T2 (de) 2006-04-06
EP0958293B1 (de) 2005-01-19
US6150416A (en) 2000-11-21
EP0958293A1 (de) 1999-11-24

Similar Documents

Publication Publication Date Title
DE69828682D1 (de) Nanomolare, non-peptidische inhibitoren von cathepsin d
ATE209191T1 (de) Parazinon thrombin inhibitoren
ID18142A (id) Inhibitor metaloprotease 1,4-heterosiklik
ID18141A (id) Inhibitor metaloprotease 1,3-diheterosiklik
ID18416A (id) Inhibitor metaloprotease diheterosiklik
ATE227283T1 (de) Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
ATE236165T1 (de) Substituierte stickstoff enthaltende heterocyclen als p38 protein kinase inhibitoren
ATE214693T1 (de) Aminoguanidine und alkoxyguanidine als protease- hemmer
NO990856L (no) Spirosykliske metallprotease-inhibitorer
ATE268781T1 (de) Thrombininhibitoren
ATE332919T1 (de) Inhibitoren von phosphoserin- und phosphothreoninspezifischen isomerasen
ID16104A (id) Inhibitor-inhibitor serin protease.
ATE264328T1 (de) Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen
ATE387448T1 (de) 4,5-pyrazinoxindole als proteinkinasehemmer
DK0941975T3 (da) Injiceringscement indeholdende korrosionshæmmere
NO20033921L (no) Inhibitor av monoaminopptak
BR0110205A (pt) Inibidores de peptìdeo deformilase
ATE282629T1 (de) Thrombininhibitoren
DE69916150T2 (de) Erfassung von Fälschungen
ATE280828T1 (de) Hemmung von alopezie
ATE433953T1 (de) Peptiddeformylaseinhibitoren
FI961299A0 (fi) Cysteinproteinasinhibitorernas genteknologiska anvaendning foer foerhindrandet av vaevnadsdegeneration
HUP9802616A2 (hu) DUEIMVIO fajtanevű, teltvirágú sötétrózsaszínű muskátli (Pelargonium Zonale Hybridae)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition